Abstract
Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tauRD), e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with ΔK280 and two proline point mutations (“anti-aggregation mutant”). The data indicate that the aggregation of tauRD is toxic, and that aggregation and toxicity can be prevented by low molecular weight compounds, notably compounds based on the N-phenylamine core. Thus the cell models are suitable for developing aggregation inhibitor drugs.
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Current Alzheimer Research
Title: N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy
Volume: 4 Issue: 4
Author(s): M. Pickhardt, J. Biernat, I. Khlistunova, Y.-P. Wang, Z. Gazova, E.-M. Mandelkow and E. Mandelkow
Affiliation:
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Abstract: Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tauRD), e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with ΔK280 and two proline point mutations (“anti-aggregation mutant”). The data indicate that the aggregation of tauRD is toxic, and that aggregation and toxicity can be prevented by low molecular weight compounds, notably compounds based on the N-phenylamine core. Thus the cell models are suitable for developing aggregation inhibitor drugs.
Export Options
About this article
Cite this article as:
Pickhardt M., Biernat J., Khlistunova I., Wang Y.-P., Gazova Z., Mandelkow E.-M. and Mandelkow E., N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788765
DOI https://dx.doi.org/10.2174/156720507781788765 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complex Polyamines: Unique Prion Disaggregating Compounds
CNS & Neurological Disorders - Drug Targets Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Prospects for Preventative Vaccines Against Prion Diseases
Protein & Peptide Letters Induction of Cytoprotective Genes Through Nrf2 / Antioxidant Response Element Pathway: A New Therapeutic Approach for the Treatment of Inflammatory Diseases
Current Pharmaceutical Design The Synthetic Oleanane Triterpenoid HIMOXOL Induces Autophagy in Breast Cancer Cells via ERK1/2 MAPK Pathway and Beclin-1 Up-regulation
Anti-Cancer Agents in Medicinal Chemistry Plant and Animal Steroids a New Hope to Search for Antiviral Agents
Current Medicinal Chemistry Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design The Stress Rheostat: An Interplay Between the Unfolded Protein Response (UPR) and Autophagy in Neurodegeneration
Current Molecular Medicine Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals
Anti-Cancer Agents in Medicinal Chemistry